Small Cap Losers: ONCR, AFIB, CBIO
4:15 pm Friday, November 12th, 2021
Oncorus Inc (NASDAQ:ONCR) is getting slammed after investors were not impressed by the initial safety, tolerability, immune activation and positive clinical response data from its ongoing Phase 1 clinical study of ONCR-177, its lead viral immunotherapy candidate, at SITC Conference. Oncorus reported that ONCR-177 was well tolerated. It said that there were no dose-limiting toxicities in heavily pretreated patients with surface lesions who were part of the dose-escalation part of the study.
The company also referred to the initial clinical response data as “positive.” Oncorus said that three of eight evaluable patients experienced clinical benefit after receiving two doses of ONCR-177.
Acutus Medical Inc (NASDAQ:AFIB) tanking to new all-time lows after the initation of AcQForce PFA-CE; JP Morgan downgraded to Underweight from Neutral earlier as well. Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally.
Catalyst Biosciences Inc (NASDAQ: CBIO) is falling to new all-time low after announcing decision to halt the clinical development of MarzAA report data to date and seek a buyer for its hemophilia assets. Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation.
